Panbela Therapeutics EBITDA 2020-2024 | PBLA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Panbela Therapeutics ebitda from 2020 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Panbela Therapeutics ebitda from 2020 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$178.6B
Regeneron Pharmaceuticals (REGN)	$127.1B
Vertex Pharmaceuticals (VRTX)	$125.3B
Gilead Sciences (GILD)	$103.1B
Bristol Myers Squibb (BMY)	$99.6B
CSL (CSLLY)	$97.7B
GSK (GSK)	$89.1B
Alnylam Pharmaceuticals (ALNY)	$34.1B
Argenex SE (ARGX)	$32.2B
BioNTech SE (BNTX)	$29.3B
Biogen (BIIB)	$28.5B
Moderna (MRNA)	$26.2B
Illumina (ILMN)	$20.6B
BeiGene (BGNE)	$19.3B
Genmab (GMAB)	$17.8B
BioMarin Pharmaceutical (BMRN)	$16.1B
Vaxcyte (PCVX)	$12.9B
Insmed (INSM)	$12.8B
Incyte (INCY)	$12.2B
Exact Sciences (EXAS)	$12.1B
Sarepta Therapeutics (SRPT)	$11.9B
Bio-Techne Corp (TECH)	$11.8B
QIAGEN (QGEN)	$10.6B
Legend Biotech (LEGN)	$9.2B
Bio-Rad Laboratories (BIO.B)	$9.1B
Roivant Sciences (ROIV)	$8.8B
Intra-Cellular Therapies (ITCI)	$8B
Halozyme Therapeutics (HALO)	$7.9B
Repligen (RGEN)	$7.8B
Exelixis (EXEL)	$7.5B